Search Results - "Hensel, Manfred"

TP53 Mutation and Survival in Chronic Lymphocytic Leukemia by ZENZ, Thorsten, EICHHORST, Barbara, HENSEL, Manfred, HALLEK, Michael, DÖHNER, Hartmut, STILGENBAUER, Stephan, BUSCH, Raymonde, DENZEL, Tina, HÄBE, Sonja, WINKLER, Dirk, BÜHLER, Andreas, EDELMANN, Jennifer, BERGMANN, Manuela, HOPFINGER, Georg

“…The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to…”
Get full text

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group by Stilgenbauer, Stephan, Zenz, Thorsten, Winkler, Dirk, Bühler, Andreas, Schlenk, Richard F., Groner, Silja, Busch, Raymonde, Hensel, Manfred, Dührsen, Ulrich, Finke, Jürgen, Dreger, Peter, Jäger, Ulrich, Lengfelder, Eva, Hohloch, Karin, Söling, Ulrike, Schlag, Rudolf, Kneba, Michael, Hallek, Michael, Döhner, Hartmut

“…The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL)…”
Get full text

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial by Cramer, Paula, Tresckow, Julia V, Robrecht, Sandra, Bahlo, Jasmin, Fürstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J, Vehling-Kaiser, Ursula, Dürig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Böttcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

“…The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve complete remissions and…”
Get full text

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma by Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W, Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut

“…Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e…”
Get full text

Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement by Weide, Rudolf, Schnell, Roland, Schardt, Christof, Koenigsmann, Michael, Otremba, Burkhard, Zahn, Mark-Oliver, Wierecky, Jan, Braun, Ute, Hensel, Manfred, Klausmann, Martine, Fleckenstein, Doris, Ehscheidt, Peter, Feiten, Stefan

“…Abstract Background The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from…”
Get full text

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial by Witzens-Harig, Mathias, Hensel, Manfred, Unterhalt, Michael, Herfarth, Klaus

“…The optimal treatment of early stage follicular Lymphoma is a matter of debate. Radiation therapy has frequently been applied with a curative approach beside…”
Get full text

Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry by Stangel, Martin, Gold, Ralf, Pittrow, David, Baumann, Ulrich, Borte, Michael, Fasshauer, Maria, Hensel, Manfred, Huscher, Dörte, Reiser, Marcel, Sommer, Claudia

“…Objectives: The management of patients with multifocal motor neuropathy (MMN) under everyday clinical conditions has been insufficiently studied. We therefore…”
Get full text

JAK2 -V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia by Krämer, Alwin, Prof, Reiter, Andreas, Prof, Kruth, Jens, MD, Erben, Philipp, MD, Hochhaus, Andreas, Prof, Müller, Martin, MD, Cross, Nicholas CP, Prof, Jones, Amy V, PhD, Ho, Anthony D, Prof, Hensel, Manfred, MD

Get full text

Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome by Dreger, Peter, Rieger, Michael, Seyfarth, Barbel, Hensel, Manfred, Kneba, Michael, Ho, Anthony D, Schmitz, Norbert, Pott, Christiane

“…From the Department of Internal Medicine V, University of Heidelberg (PD, MR, MH, ADH); Department of Internal Medicine, Westpfalz-Klinikum, Kaiserslautern…”
Get full text

The bcl-2/IgH rearrangement in a population of 204 healthy individuals: Occurrence, age and gender distribution, breakpoints, and detection method validity by Schmitt, Christina, Balogh, Brigitta, Grundt, Alexander, Buchholtz, Christian, Leo, Albrecht, Benner, Axel, Hensel, Manfred, Ho, Anthony D., Leo, Eugen

“…This study assessed prevalence, frequency, age and gender distribution and breakpoint locations, and detection method validity for the bcl-2/IgH rearrangement…”
Get full text

Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients by Welz, Tanya, Wyen, Christoph, Hensel, Manfred

“…The number of patients with HIV (human immunodeficiency virus) requiring treatment for malignancy is increasing worldwide. Concurrent treatment of HIV and…”
Get more information

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial by Barrington, Sally F, Belada, David, Meignan, Michel, Ptáčník, Václav, Fingerle-Rowson, Günter R, Hiddemann, Wolfgang, Marcus, Robert E, Grigg, Andrew, Quach, Hang, Marlton, Paula, Offner, Fritz, Van eygen, Koen, Roitman, Daryl, Trneny, Marek, Le Du, Katell, Solal-Celigny, Philippe, Cartron, Guillaume, Foussard, Charles, Schmidt, Peter, Sökler, Martin, Schimmelpfennig, Christoph, Tonndorf, Solveig, Hänel, Mathias, Hess, Georg, Schalk, Enrico, Pfreundschuh, Michael, Herold, Michael, Forstpointner, Roswitha, Vehling-Kaiser, Ursula, Majolino, Ignazio, Balzarotti, Monica, Soler Campos, Alfonso, Marquez Navarro, Jose Antonio, Grande Garcia, Carlos, Nilsson-Ehle, Herman, Radford, John, Kruger, Anton, Culligan, Dominic, Dyer, Martin, Pettengell, Ruth, Al-Ismail, Saad, Al-Refaie, Faris, Blesing, Norbert, Macnamara, Christopher, O'callaghan, Ann, Haynes, Andrew, Bowles, Kristian, Gallop-Evans, Eve, Bailey, James, De Oliveira, Moacyr, Tezcan, Haluk, Kim, Kevin, Hatake, Kiyohiko, Ogura, Michinori, Uchida, Toshiki, Kinoshita, Tomohiro, Kirsch, Andreas, Koenigsmann, Michael, Dürig, Jan, Kneba, Michael, Bergmann, Lothar, Marks, Reinhard, Wulf, Gerald, Schmits, Rudolf, Lengfelder, Eva, Scott, Fiona, Taniwaki, Masafumi, Yoshida, Isao, Uike, Naokuni, Kamitsuji, Yuri, Iida, Shinsuke, Ohmine, Ken, Nosaka, Kisato, Ide, Kazuhiko, Ishikawa, Takayuki, Li, Wei, Yu, Li, Shi, Yuan Kai, Hong, Xiaonan, Feng, Jifeng, Zhan, Rong, Lin, Tongyu, Costello, Regis, Tournilhac, Olivier, Kirchen, Heinz, Hebart, Holger, Gurion, Ronit, Shpilberg, Ofer, Leoni, Pietro, Samoylova, Olga, Usui, Noriko, Izutsu, Koji, Ichinohe, Tatsuo, Kubo, Kohmei, Ishida, Fumihiro, Dakhil, Shaker, Maruyama, Dai, Kobayashi, Tsutomu, Wada, Katsuya, Minami, Yosuke

“…Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line…”
Get full text

Drug-perturbation-based stratification of blood cancer by Dietrich, Sascha, Oleś, Małgorzata, Lu, Junyan, Sellner, Leopold, Anders, Simon, Velten, Britta, Wu, Bian, Hüllein, Jennifer, da Silva Liberio, Michelle, Walther, Tatjana, Wagner, Lena, Rabe, Sophie, Ghidelli-Disse, Sonja, Bantscheff, Marcus, Oleś, Andrzej K, Słabicki, Mikołaj, Mock, Andreas, Oakes, Christopher C, Wang, Shihui, Oppermann, Sina, Lukas, Marina, Kim, Vladislav, Sill, Martin, Benner, Axel, Jauch, Anna, Sutton, Lesley Ann, Young, Emma, Rosenquist, Richard, Liu, Xiyang, Jethwa, Alexander, Lee, Kwang Seok, Lewis, Joe, Putzker, Kerstin, Lutz, Christoph, Rossi, Davide, Mokhir, Andriy, Oellerich, Thomas, Zirlik, Katja, Herling, Marco, Nguyen-Khac, Florence, Plass, Christoph, Andersson, Emma, Mustjoki, Satu, von Kalle, Christof, Ho, Anthony D, Hensel, Manfred, Dürig, Jan, Ringshausen, Ingo, Zapatka, Marc, Huber, Wolfgang, Zenz, Thorsten

“…As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional…”
Get full text

High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany by Feiten, Stefan, Chakupurakal, Geothy, Feustel, Hans Peter, Maasberg, Michael, Otremba, Burkhard, Ehscheidt, Peter, Hensel, Manfred, Hansen, Richard, Weide, Rudolf

“…Purpose Immunomodulatory drugs (IMIDS) have changed the treatment and outcome of patients suffering from multiple myeloma. However, with the oral…”
Get full text

Response to the letter to the Editor concerning our article “High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany” by Feiten, Stefan, Chakupurakal, Geothy, Feustel, Hans Peter, Maasberg, Michael, Otremba, Burkhard, Ehscheidt, Peter, Hensel, Manfred, Hansen, Richard, Weide, Rudolf

Get full text

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial by Ton, Gigi Nu Hoang Quy, Kriegsmann, Katharina, Awwad, Mohamed H.S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor Wolfgang, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Neubauer, Andreas, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe, Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja, Salwender, Hans, Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., Hundemer, Michael

“…Introduction: Elotuzumab, a monoclonal antibody targeting SLAM family member 7 protein (SLAMF7) on multiple myeloma (MM) cells, has shown promise in…”
Get full text

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia by Eichhorst, Barbara F., Busch, Raymonde, Hopfinger, Georg, Pasold, Rita, Hensel, Manfred, Steinbrecher, Cordelia, Siehl, Siegfried, Jäger, Ulrich, Bergmann, Manuela, Stilgenbauer, Stephan, Schweighofer, Carmen, Wendtner, Clemens M., Döhner, Hartmut, Brittinger, Günter, Emmerich, Bertold, Hallek, Michael

“…Combination chemotherapy with fludarabine plus cyclophosphamide (FC) was compared with the standard regimen of fludarabine monotherapy in first-line treatment…”
Get full text

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study by Kriegsmann, Katharina, Ton, Gigi Nu Hoang Quy, Awwad, Mohamed H. S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Munder, Markus, Dürig, Jan, Blau, Igor W., Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja C., Salwender, Hans J., Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., Hundemer, Michael

Get full text

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial) by Rummel, Mathias J, Lerchenmüller, Christian, Hensel, Manfred, Goerner, Martin, Buske, Christian, Schulz, Holger, Schmidt, Burkhard, Kojouharoff, Georgi, Lange, Elisabeth, Willenbacher, Wolfgang, Dürig, Jan, Engel, Erik, Kauff, Frank, Barth, Jürgen, Burchardt, Alexander Christoph, Hinke, Axel, Wupperfeld, Jasmin, Greil, Richard

“…Background: The StiL NHL1-2003 trial demonstrated that Bendamustine-Rituximab (B-R) is a highly effective treatment for patients with WM achieving a median PFS…”
Get full text

Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG) by Hentrich, Marcus, Hoffmann, Christian, Mosthaf, Franz, Müller, Markus, Siehl, Jan, Wyen, Christoph, Hensel, Manfred

“…AIDS-related aggressive B cell lymphoma (HIV-NHL) is the second most common HIV-associated malignancy. In contrast, Hodgkin-lymphoma (HL) is one of the most…”
Get full text